to make prescription drugs more affordable
Make prescription drugs more affordable.
Occurrences
to make prescription drugs more affordable
She will continue to work to bring down the cost of prescription drugs.
Evidence
"Rep. Schrier ... has introduced a bipartisan bill that will bring down the cost of insulin." The release says the bill "paves the way for less expensive versions of brand name insulins."
Roll Call 420 lists H.R. 5376, the Inflation Reduction Act, on motion to concur in the Senate amendment, with the result marked Passed.
Schrier said the bill "will bring down costs for families" and listed "Allowing Medicare to negotiate lower drug prices" and "Capping insulin costs for seniors at $35/month."
CMS states the law lowers prescription drug prices in Medicare through price negotiation, caps out-of-pocket prescription drug costs at $2,000 in 2025, and caps insulin at $35 per month for Medicare beneficiaries.
Assessments
Kim Schrier can claim partial fulfillment. During her House term, she voted for the Inflation Reduction Act, which became law in 2022 and produced real prescription-drug affordability gains, including Medicare drug-price negotiation, a $35 monthly insulin cap for Medicare beneficiaries, and a $2,000 annual out-of-pocket cap starting in 2025. That matches the promise in a meaningful but limited way. Full delivery is too strong because the reforms were narrower than a broad promise to make prescription drugs affordable overall: they mainly targeted Medicare beneficiaries and selected drugs, and Schrier's role was supportive rather than singular. Her earlier insulin-pricing bill shows serious effort, but the strongest evidence of delivery is the enacted federal law she helped advance in the same term.
Schrier supported and voted for the Inflation Reduction Act during the same term, and federal implementation produced concrete prescription-drug affordability gains, including Medicare drug price negotiation, a $35 monthly insulin cap for Medicare beneficiaries, and a $2,000 annual out-of-pocket cap beginning in 2025. However, the promise was broad, and the enacted reforms mainly applied to Medicare beneficiaries and selected drugs rather than making prescription drugs broadly affordable for all patients, so the outcome is partial rather than fully delivered.